<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332888</url>
  </required_header>
  <id_info>
    <org_study_id>ICFEr-RITU2</org_study_id>
    <nct_id>NCT03332888</nct_id>
  </id_info>
  <brief_title>Safety of HMA-CD20 in Patients With HFrEF</brief_title>
  <acronym>ICFEr-RITU2</acronym>
  <official_title>Phase II Clinical Trial Testing the Safety of a Humanized Monoclonal Antibody Anti-CD20 in Patients With Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a phase II single-centered, single group, prospective clinical trial to evaluate&#xD;
      the safety of HMA-CD20 doses among stable patients with class III/IV according to the NYHA&#xD;
      classification with HFrEF receiving standard of care therapy. The index qualifying HFrEF must&#xD;
      have EF &amp;lt; 40% based on echocardiographic or cardiac MRI techniques, heart failure class&#xD;
      III/IV according to the NYHA classification,aged 40-60 years, being diagnosed less than 12&#xD;
      months before enrollment of study, following the standard heart failure treatment regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Rituximab Emergent Cardiovascular Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>The investigators analyze the safety of rituximab based on the occurrence of cardiovascular adverse events such as arrhythmia, worsening of symptoms and acute coronary syndromes.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Interventional Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For this trial, HMA-CD20 will be given as an intravenous infusion of 1000 mg I.V twice in a month separating them by fourteen days starting at the baseline visit. The dose for both HMA-CD20 dosages willbe identical at the screening visit after the participant's eligibility has been established, and it will remain thesame for both infusions. The standard dose for HMA-CD20 is 1,000 mg per intravenous infusion on day 1 and day 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab will be studied in patients with HFrEF, and verify the patients safety.</description>
    <arm_group_label>Interventional Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        4.1 Inclusion criteria&#xD;
&#xD;
          1. Men and women (women not pregnant neither in lactation period) between ≥ 40 to 60&#xD;
             years-old.&#xD;
&#xD;
          2. Diagnosis of HFrEF and functional class III-IV.&#xD;
&#xD;
          3. EF ≤ 40% evaluated by MRI and or transthoracic echocardiography, with validity of&#xD;
             twelve months.&#xD;
&#xD;
          4. Inadequate response to standard treatment.&#xD;
&#xD;
          5. Urgent medical attention or hospitalization due to worsening of HF or MI in the last&#xD;
             12 months.&#xD;
&#xD;
          6. Diagnosis of ischemic or non ischemic dilated cardiomyopathy.&#xD;
&#xD;
          7. Life expectancy of at least six months, in investigator opinion.&#xD;
&#xD;
          8. Participants should sign an (informed consent form) ICF form personally.&#xD;
&#xD;
        4.2 Exclusion criteria&#xD;
&#xD;
          1. Severe primary valvular cardiopathy or valvular prosthesis (mechanical or bio-valve).&#xD;
&#xD;
          2. History of heart transplant surgery, cardiomyoplasty, left ventricular reduction&#xD;
             surgery, valvuloplasty, implantation of a ventricle assist device (VAD) and surgical&#xD;
             cardiac congenital defect correction.&#xD;
&#xD;
          3. Uncontrolled atrial fibrillation (HR &gt; 100 bpm), atrial flutter, sustained atrial&#xD;
             fibrillation and / or significant arrhythmias such as sustained or unsustained&#xD;
             ventricular tachychardia, bigeminy or trigeminy evidenced by Holter during the&#xD;
             prescreening period.&#xD;
&#xD;
          4. Implantable cardioverter defibrillator (ICD) within the last three months.&#xD;
&#xD;
          5. Acute coronary syndromes that required pharmacological or mechanical reperfusion or&#xD;
             medical treatment, within 30 days before selection.&#xD;
&#xD;
          6. Percutaneous coronary intervention within 30 days prior to selection.&#xD;
&#xD;
          7. Treatment with inotropic agents (dobutamine, milrinone, levosimendan), I.V. diuretics&#xD;
             or vasodilators within 30 days of selection.&#xD;
&#xD;
          8. Pregnant women or breast feeding period without adequate prenatal care.&#xD;
&#xD;
          9. Untreated thyroid disease.&#xD;
&#xD;
         10. Patients with GFR &lt;30mL/min based on the cockcroft-gualt formula&#xD;
&#xD;
         11. Rapidly progressive glomerulonephritis, seizures or psychosis, progressive neuropathy&#xD;
             or myopathy.&#xD;
&#xD;
         12. Hemoglobin: &lt; 8.5 mg/dL.&#xD;
&#xD;
         13. WBC count less than 5000/mm3&#xD;
&#xD;
         14. Platelets: &lt;100,000/mm, AST or ALT &gt;2.5 × upper limit of normal (ULN) unless related&#xD;
             to primary disease.&#xD;
&#xD;
         15. Positive Hepatitis B or C serology (Hep B Surface antigen and Hep C antibody).&#xD;
&#xD;
         16. History of positive HIV.&#xD;
&#xD;
         17. Treatment with any investigational agent within 4 weeks of screening or 5 half-lives&#xD;
             of the investigational drug (whichever is longer).&#xD;
&#xD;
         18. Recipients of an available attenuated vaccine within four weeks prior to&#xD;
             randomization.&#xD;
&#xD;
         19. Previous treatment with HMA-CD20 or any immunotherapy.&#xD;
&#xD;
         20. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies.&#xD;
&#xD;
         21. Known active bacterial, viral, fungal (excluding fungal infections of nail&#xD;
             beds/onychomycosis), mycobacterial, or other infection (including tuberculosis or&#xD;
             atypical mycobacterial disease) or any major episode of infection requiring&#xD;
             hospitalization or treatment with I.V. antibiotics within four weeks of screening, or&#xD;
             oral antibiotics within two weeks before screening.&#xD;
&#xD;
         22. Consistent steroid administration within the past four weeks.&#xD;
&#xD;
         23. Lack of peripheral venous access.&#xD;
&#xD;
         24. Concomitant or previous malignancies, except curatively resected non-melanoma skin&#xD;
             carcinomas or carcinoma in situ of the cervix.&#xD;
&#xD;
         25. History of psychiatric disorder that would interfere with participation in this&#xD;
             protocol, such as depression, bipolar syndrome, schizophrenia.&#xD;
&#xD;
         26. Patients with concomitant severe COPD or emphysema.&#xD;
&#xD;
         27. Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the patient at high risk from treatment&#xD;
             complications.&#xD;
&#xD;
         28. Female participants without adequate method of contraception&#xD;
&#xD;
         29. Inability to comply/assist with study and follow-up procedures.&#xD;
&#xD;
        4.3 Elimination criteria&#xD;
&#xD;
          1. Progression of NYHA functional class since the initiation of the study.&#xD;
&#xD;
          2. BNP or troponin I elevation&#xD;
&#xD;
          3. New onset of pulmonary infection due to opportunistic virulent antigens (N. Jirovecci,&#xD;
             A. Baumanni, MRSA, VRSA).&#xD;
&#xD;
          4. Any serious adverse event (SAE) indicative of fatal or nonfatal hepatitis, liver&#xD;
             failure or its complications.&#xD;
&#xD;
          5. ALT or AST &gt;3x normal values with a total bilirubin ≥ 2x normal value.&#xD;
&#xD;
          6. WBC count &lt; 3000/mm3&#xD;
&#xD;
          7. Anaphylactic or life-threatening hypersensitivity reactions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos Jerjes Sanchez Diaz, MD</last_name>
    <phone>+518188880464</phone>
    <email>carlos.jerjes@udicem.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Adolfo Sanchez-Trujillo, MD</last_name>
    <phone>+518188880464</phone>
    <email>alfalui02@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud</investigator_affiliation>
    <investigator_full_name>David Rodriguez</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

